Riociguat denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Riociguat

Riociguat (Adempas) treats serious cardiopulmonary conditions and carries a meaningful cost, which is why BCBS places it on a tier requiring prior authorization (PA) before dispensing. A PA denial — or a claim denial because PA was never obtained — does not mean the drug is inappropriate for you. It means the insurer's process was not completed before the prescription was filled, or the submitted clinical information did not satisfy BCBS's coverage criteria at the time of review.

## Why This Denial Is Appealable

If you have an active PA denial or a claim denial due to missing PA, you can appeal on two grounds: (1) the clinical information now in hand fully satisfies BCBS's coverage criteria, and (2) if your prescriber tried to obtain PA and was given incorrect guidance, you may also argue a plan-administration error. Appeals succeed most often when the clinical record is complete, well-organized, and directly maps to every criterion in the insurer's published policy.

## Federal Appeal Framework

• Internal appeal: Submit a written internal appeal to BCBS within the timeframe shown on your denial notice. Under ACA §2719 and ERISA §503, plans must provide a meaningful review and issue a written decision with the specific reasons for any continued denial.
• External review: A denial upheld after internal appeal may be submitted to an IRO for independent external review. Federal rules generally allow approximately four months from the internal-appeal decision to file for external review.
• Expedited PA: For ongoing or urgent treatment, simultaneously request an expedited PA review and an expedited internal appeal if your health could be seriously harmed by delay.

## Documentation to Gather

• Clinical diagnosis documentation: Specialist notes, diagnostic test results, and imaging confirming the condition and its severity classification.
• Prescriber medical-necessity letter: Should explain why riociguat is the appropriate choice given the patient's specific clinical profile.
• Prior-treatment record: Dated list of all prior therapies tried, doses used, duration, and reason for discontinuation or inadequate response — formatted to match BCBS's step-therapy requirements if applicable.
• BCBS coverage policy: Download BCBS's current published medical or coverage policy for riociguat and use it as your checklist.

## Criteria-Mapping Structure

Print BCBS's PA criteria. For each criterion, write a one-sentence response citing the exact document, date, and finding in your medical record that satisfies it. Where a criterion references the FDA label (e.g., approved indication, risk program enrollment), attach the relevant label excerpt. Submitting a pre-organized table dramatically reduces the reviewer's discretion to deny on technicalities.